1 insider bought €4,396 of shares over the last 90 days, the latest by 박병욱, filed 28 Oct 2026.
Genoray Co., Ltd.: what insiders have been doing
Every trade that managers of Genoray Co., Ltd. disclose to DART (FSS) is tracked on this page. The company sits in the Health Care sector. Over the twelve months to 31 October 2026, 17 filings were filed, from 9 insiders.
Open-market activity splits into 11 purchases totalling €10k and 2 sales totalling €45k; 7 insiders sit on the buying side and 2 insiders on the selling side. The totals do not cover 9 filings with an undisclosed amount. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. At €23k, the sale published on 8 April 2026 by 노구영 is the largest of the period (0.090% of market cap). Among those who bought: 3 senior executives, 2 board members and 1 major shareholder.
The last insider purchase was made public on 28 October 2026, 12 days ago. Typically, a trade is published a median of 2 days after it takes place. The shorter that gap, the sooner other investors can see what insiders have done.
With 17 filings in twelve months, the company is more active than the median of 7 filings across the 2,655 companies we follow on the same exchange. Since 2021, the database holds 33 purchases and 2 sales by insiders of the company.
For comparison within the same sector, see the insider buying recorded at Dynavox Group AB and UCB. Source: insider filings from DART (FSS). Past trades are no guide to future returns.
Who traded when
BuySale+4 other insiders
Since the insiders bought
- -33.9%Entry ₩4,675 · Close 29 Oct 2026 ₩3,090
- -28.6%Entry ₩4,325 · Close 29 Oct 2026 ₩3,090
- -17.4%Entry ₩7,060 · Close at T+365 ₩5,830
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
- 2,107 sharesShareKRXDART:20261028000293Canonical exit: 26 Jan 2027 (T+90)
- Other0DART
- Other0DART
- Other0DART
- Other0DART
- Other0DART
- 2,000 sharesShareKRXDART:20260701000028Canonical exit: 29 Sept 2026 (T+90)
- 5,000 sharesShareKRXDART:20260629000286Canonical exit: 27 Sept 2026 (T+90)
- ●Executives0DART
- 2,000 sharesKRXDART:20260611000455Canonical exit: 9 Sept 2026 (T+90)
- 2,000 sharesShareKRXDART:20260611000437Canonical exit: 9 Sept 2026 (T+90)
- 0KRXDART:20260527000235
- 1,400 shares@ ₩4,645.000.015% mcap100.0% of flowShareKRXDART:20260424000308Canonical exit: 22 Jul 2026 (T+90)
- 8,448 shares0.089% mcap77.9% of flowKRXDART:20260421000286
- 8,448 shares@ ₩4,682.23480.090% mcap100.0% of flowShareKRXDART:20260408003017
- 2,500 shares0.025% mcap22.1% of flowKRXDART:20260318000769Canonical exit: 14 Jun 2026 (T+90)
- ●Executives0DART
- 2,500 sharesShareKRXDART:20260203000292Canonical exit: 4 May 2026 (T+90)
- 1,000,000 sharesKRXDART:20260130000468Canonical exit: 30 Apr 2026 (T+90)
- 1,300 sharesShareKRXDART:20260127000084Canonical exit: 27 Apr 2026 (T+90)
- 1,000 sharesShareKRXDART:20251223000199Canonical exit: 23 Mar 2026 (T+90)
- ●Executives0DART
- 10,000 sharesShareKRXDART:20250527000188Canonical exit: 25 Aug 2025 (T+90)
- 381 sharesShareKRXDART:20250108000049Canonical exit: 8 Apr 2025 (T+90)
- 0KRXDART:20241212000050
25 of 49 declarations
About Genoray Co., Ltd.
Genorey is a company operating in the healthcare and pharmaceutical sector, listed on the XKRX market. It focuses on the development and commercialization of innovative pharmaceutical products.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
